Arxis, Inc. is a clinical-stage biotechnology company dedicated to the development and commercialization of innovative therapies for patients suffering from respiratory diseases. The company's primary focus is on addressing significant unmet medical needs in conditions such as chronic obstructive pulmonary disease (COPD) and asthma. Arxis leverages its proprietary technology platform to design and develop novel drug candidates that target specific biological pathways involved in respiratory inflammation and airway remodeling. Its lead product candidate, ARX-101, is an inhaled small molecule being evaluated for its potential to improve lung function and reduce exacerbations in patients with severe respiratory conditions. By utilizing a lung-targeted drug delivery approach, Arxis aims to maximize therapeutic efficacy at the site of disease while minimizing systemic side effects. The company's strategy involves advancing its clinical pipeline through rigorous testing and seeking regulatory approvals to bring life-changing treatments to a global patient population. Arxis is headquartered in the United States and continues to invest in research and development to expand its portfolio of respiratory-focused therapeutics.
Market capitalization, or "market cap", is the aggregate market value of a company represented in a dollar amount. Since it represents the “market” value of a company, it is computed based on the current market price (CMP) of its shares and the total number of outstanding shares.
Enterprise value (EV) measures a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt and any cash or cash equivalents on the company's balance sheet.
The enterprise value-to-revenue multiple (EV/R) is a measure of the value of a stock that compares a company's enterprise value to its revenue. EV/R is one of several fundamental indicators that investors use to determine whether a stock is priced fairly. The EV/R multiple is also often used to determine a company's valuation in the case of a potential acquisition. It's also called the enterprise value-to-sales multiple.
The enterprise value to earnings before interest, taxes, depreciation, and amortization ratio (EV/EBITDA) compares the value of a company—debt included—to the company's cash earnings less non-cash expenses. It's best to use the EV/EBITDA metric when comparing companies within the same industry or sector. Typically, when evaluating a company, an EV/EBITDA value below 10 is seen as healthy.
It follows the same logic as the EV/EBITDA indicator, but instead of EBITDA, EBIT is used, which considers non-cash D&A expenses in the company's operating result.
...and much more!